Pricing Log in Create free account
Friday 6 November 2026 Export PTGX’s income statement to Excel — free account

Protagonist Therapeutics, Inc.

PTGX Healthcare Biotechnology

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.

Revenue
+3,749.2%
EPS
+549.1%
Free cash flow
+839.7%

Quarter to June 2026, against a year earlier

131.81 3.45 −2.55%
Market cap
$8.8B
P/E
111×
Fwd P/E
31.2×
Dividend yield
—
F-score
4/9
Altman Z
61.55
Beneish M
−7.18
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Protagonist Therapeutics, Inc. 10-Q filed Aug 5, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:17 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed May 5, 2026: no comparison — the earlier filing's Item cannot be compared